Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD
Clinical Journal of the American Society of Nephrology · 2025-09 · 20 (9) · 1206-1214
DOI: 10.2215/cjn.0000000771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 14.07.2025. Verfasst von Megumi Oshima und 13 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Menarini Group, National Health and Medical Research Council, Ramaciotti Foundations, Menarini Group, National Health and Medical Research Council.
Abstract (Originalsprache)
Key Points In this post hoc analysis of Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation, canagliflozin reduced the risk of first and subsequent all-cause hospitalization by 14%. Sodium-glucose cotransporter 2 inhibitor reduced the risk of hospitalization by 15%, with consistent effects irrespective of kidney function, albuminuria, and diabetes status. Absolute reductions in hospitalizations with sodium-glucose cotransporter 2 inhibitor in patients with CKD are substantial, with major implications for individuals and health systems.
Background
Unplanned hospitalization, irrespective of cause, is a meaningful outcome for patients, caregivers, clinicians, and health systems. The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on all-cause hospitalization in patients with CKD have not been systematically evaluated.
Methods
We conducted a post hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial to evaluate the effect of canagliflozin on nonelective all-cause hospitalization using Cox proportional hazards models, with recurrent events analysis to assess effects on first and subsequent hospitalizations. We performed inverse variance weighted meta-analysis of three placebo-controlled SGLT2 inhibitor CKD-focused trials to assess the relative and absolute effects of SGLT2 inhibitors on first and subsequent all-cause hospitalizations overall and across clinically relevant subgroups. For analyses of cause-specific hospitalization, adverse events that were reported by investigators but not adjudicated were used.
Results
Over a median follow-up of 2.6 years, 3015 hospitalizations occurred among 1543 of 4401 (35%) participants in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial. Compared with placebo, canagliflozin reduced the risk of first all-cause hospitalization (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.80 to 0.98; P = 0.02) and first and subsequent hospitalizations (HR, 0.86; 95% CI, 0.76 to 0.96; P = 0.007). In a meta-analysis of three placebo-controlled SGLT2 inhibitor CKD-focused trials, SGLT2 inhibitors reduced the risk of first and subsequent hospitalizations from any cause by 15% (HR, 0.85; 95% CI, 0.78 to 0.95; P < 0.001), with consistent effects irrespective of diabetes, baseline kidney function, and albuminuria (all P interactions > 0.50). Reductions were driven by hospitalizations due to infection, cardiac, renal or urinary, and metabolism or nutritional disorders. We estimated that SGLT2 inhibition in CKD would prevent 36 (95% CI, 13 to 56) unplanned hospitalizations per 1000 patient-years of treatment, across a broad range of patients.
Conclusions
SGLT2 inhibitors reduce the risk of hospitalizations from any cause in patients with CKD, irrespective of diabetes status, kidney function, and degree of albuminuria. Clinical Trial registry name and registration number: NCT02065791. Podcast This article contains a podcast at https:// dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2025_09_30_CJASNSeptember.20.9.mp3
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
- Department of Nephrology and Rheumatology, Kanazawa University, Kanazawa, Japan.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
- Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
- Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California.
- Department of Renal Medicine, University College London, London, United Kingdom.
ORCID-Profile: Niels Jongs, Adeera Levin, Glenn M Chertow, David C Wheeler, Hiddo J L Heerspink, Clare Arnott, Meg J Jardine, Kenneth W Mahaffey, Carol Pollock, William G Herrington, Brendon L Neuen
Förderung
- Menarini Group, National Health and Medical Research Council, Ramaciotti Foundations
- Menarini Group
- National Health and Medical Research Council
- Ramaciotti Foundations
Zitieren
APA
Oshima, M., Buizen, L., Jongs, N., Levin, A., Chertow, G. M., Wheeler, D. C., Heerspink, H. J. L., Arnott, C., Jardine, M. J., Mahaffey, K. W., Pollock, C., Herrington, W. G., Perkovic, V., & Neuen, B. L. (2025). Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD. Clinical Journal of the American Society of Nephrology, 20(9), 1206-1214. https://doi.org/10.2215/cjn.0000000771
Vancouver
Oshima M, Buizen L, Jongs N, Levin A, Chertow GM, Wheeler DC, et al. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD. Clinical Journal of the American Society of Nephrology. 2025;20(9):1206-1214. doi:10.2215/cjn.0000000771
BibTeX
@article{Oshima2025,
author = {Oshima, Megumi and Buizen, Luke and Jongs, Niels and Levin, Adeera and Chertow, Glenn M and Wheeler, David C and Heerspink, Hiddo J L and Arnott, Clare and Jardine, Meg J and Mahaffey, Kenneth W and Pollock, Carol and Herrington, William G and Perkovic, Vlado and Neuen, Brendon L},
title = {Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {9},
pages = {1206--1214},
doi = {10.2215/cjn.0000000771}
}
EUVIMED